A comprehensive analysis of POLE / POLD1 genomic alterations in colorectal cancer
The Oncologist · 2024
DOI: 10.1093/oncolo/oyae098 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2024. Verfasst von Osama Mosalem und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Colorectal Neoplasms, DNA Polymerase II, Poly-ADP-Ribose Binding Proteins, DNA Polymerase III. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Tempus AI.
Abstract (Originalsprache)
Introduction
Pathogenic mutations in POLE/POLD1 lead to decreased fidelity of DNA replication, resulting in a high tumor mutational burden (TMB-H), defined as TMB ≥ 10 mut/Mb, independent of deficient mismatch repair (dMMR) and microsatellite instability high (MSI-H) status.
Methods
De-identified records of patients with colorectal cancer (CRC) profiled with the Tempus xT assay (DNA-seq of 595-648 genes at 500×) were identified from the Tempus Database.
Results
Among 9136 CRC samples profiled, the frequency of POLE/POLD1 genomic alterations was 2.4% (n = 217). Copy number loss was the most common genomic alteration (64%, n = 138) of POLE/POLD1, followed by copy number amplifications (18%, n = 40) and short variant mutations (18%, n = 39). The POLE/POLD1 mutated group presented with a higher frequency of TMB-H phenotype relative to wild type (WT; 22% vs. 9%, P < .001), with a median TMB of 127 mut/Mb in the TMB-H POLE/POLD1 subset. The TMB showed a dramatic contrast between POLE/POLD1 short variant mutations as compared to the group with copy number alterations, with a TMB of 159 mut/Mb vs 15 mut/Mb, respectively. Thus, the short variant mutations represented the so-called ultra-hypermutated phenotype. The POLE/POLD1 mutated group, as compared to WT, exhibited a higher rate of coexisting mutations, including APC, ALK, ATM, BRCA2, and RET mutations.
Conclusion
Patients with POLE/POLD1 mutations exhibited significant differences across immunological markers (ie, TMB, MMR, and MSI-H) and molecular co-alterations. Those with short variant mutations represented 18% of the POLE/POLD1 cohort and 0.4% of the total cohort examined. This group of patients had a median TMB of 159 mut/Mb (range 34-488), representing the ultra-hypermutated phenotype. This group of patients is important to identify given the potential for exceptional response to immune checkpoint inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
- Department of Medicine, Division of Medical Oncology, Duke Cancer Center, Raleigh, NC, USA.
- Tempus AI, Chicago, IL, USA.
- Department of Medicine, Division of Hematology and Oncology, Mayo Clinic, Phoenix, AZ, USA.
ORCID-Profile: Osama Mosalem, Tucker W Coston, Robin Imperial, Elizabeth Mauer, Tanios S Bekaii-Saab, Jason S Starr
Förderung
- Tempus AI
Zitieren
APA
Mosalem, O., Coston, T. W., Imperial, R., Mauer, E., Thompson, C., Yilma, B., Bekaii-Saab, T. S., Stoppler, M. C., & Starr, J. S. (2024). A comprehensive analysis of POLE / POLD1 genomic alterations in colorectal cancer. The Oncologist. https://doi.org/10.1093/oncolo/oyae098
Vancouver
Mosalem O, Coston TW, Imperial R, Mauer E, Thompson C, Yilma B, et al. A comprehensive analysis of POLE / POLD1 genomic alterations in colorectal cancer. The Oncologist. 2024. doi:10.1093/oncolo/oyae098
BibTeX
@article{Mosalem2024,
author = {Mosalem, Osama and Coston, Tucker W and Imperial, Robin and Mauer, Elizabeth and Thompson, Christopher and Yilma, Binyam and Bekaii-Saab, Tanios S and Stoppler, Melissa Conrad and Starr, Jason S},
title = {A comprehensive analysis of POLE / POLD1 genomic alterations in colorectal cancer},
journal = {The Oncologist},
year = {2024},
doi = {10.1093/oncolo/oyae098}
}
EUVIMED